Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS4464 in Multiple Myeloma or Lymphoma
NCT02978235Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS4464 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Taiho Oncology. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Mar 2017; status: terminated.
02
Drugs
TAS4464
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02978235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978235.